Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phlebothrombosis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Phlebothrombosis. Displaying page 1 of 1.
    EudraCT Number: 2017-000648-16 Sponsor Protocol Number: BAY59-7939/19365 Start Date*: 2017-06-21
    Sponsor Name:Bayer AG
    Full Title: Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 10 mg granules for oral suspension rivaroxaban versus 10 mg tablets rivaroxaban under fasted condition in healthy subjects
    Medical condition: Prevention and treatment of thromboembolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10043640 Thrombosis venous LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004373-23 Sponsor Protocol Number: ROV-BEM-2003-02 Start Date*: 2007-08-14
    Sponsor Name:LABORATORIOS FARMACEUTICOS ROVI, S.A.
    Full Title: MULTICENTRIC, RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND THE SAFETY OF THE PROPHYLAXIS WITH BEMIPARIN 3,500 IU/day FOR 28 DAYS COMPARED TO 8 DAYS, IN V...
    Medical condition: VENOUS THROMBOEMBOLIC DISEASE IN PATIENTS UNDERGOING ONCOLOGICAL ABDOMINAL OR PELVIC SURGERY
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043640 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000609-18 Sponsor Protocol Number: BAY59-7939/19366 Start Date*: 2017-06-20
    Sponsor Name:Bayer AG
    Full Title: Single-dose, open-label, randomized, 2-way crossover bioequivalence study of 20 mg granules for oral suspension rivaroxaban versus 20 mg tablets rivaroxaban under fed condition in healthy subjects
    Medical condition: Prevention and treatment of thromboembolic disorders
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004866 10043640 Thrombosis venous LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-004199-11 Sponsor Protocol Number: NOSTRADAMUS Start Date*: 2007-02-16
    Sponsor Name:Academic Medical Center
    Full Title: NOSTRADAMUS: Testing for thrombophilia in patients with a first episode of venous thromboembolism: a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs.
    Medical condition: A randomized controlled trial of testing and no testing for thrombophilia in patients with a first episode of venous thrombosis or pulmonary embolism (venous thromboembolism, VTE) will be performed...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10047249 Venous thrombosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002511-83 Sponsor Protocol Number: TTP889-201 Start Date*: 2005-01-03
    Sponsor Name:TransTech Pharma
    Full Title: A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Three Weeks Extended VTE Prophylaxis with Daily Oral Doses of TTP889 After One Week of Standard Prophylactic Treatment Fo...
    Medical condition: Antithrombotic in patients at risk for venous thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    7 10047249 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002433-31 Sponsor Protocol Number: 29BRC17.0125 Start Date*: 2017-09-13
    Sponsor Name:CHRU de BREST
    Full Title: REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial
    Medical condition: Patients with indications for long-term anticoagulation after VTE (i.e.; symptomatic PE or proximal DVT) initially treated during 6 to 12 months with anticoagulant therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10047249 Venous thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000570-33 Sponsor Protocol Number: FAAI2.10.2018 Start Date*: 2019-09-26
    Sponsor Name:FONDAZIONE ARIANNA ANTICOAGULAZIONE
    Full Title: The Jason study: Sulodexide (VESSEL®) for the prevention of recurrent venous thromboembolism in elderly patients after a first episode of venous thrombembolism (VTE)
    Medical condition: Prevention of recurrence after a first episode of VTE
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004866 10043640 Thrombosis venous LLT
    20.0 100000004855 10034191 PE LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000539-29 Sponsor Protocol Number: 2018.02.08 Start Date*: 2018-12-11
    Sponsor Name:Hamilton Health Sciences Corporation
    Full Title: PeriOperative ISchemic Evaluation-3 (POISE-3) Trial
    Medical condition: The occurrence of life-threatening, major, and critical organ bleeding, and, major arterial and venous thrombosis in patients undergoing noncardiac surgery. And for patients in the blood pressure m...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10043611 Thrombosis arterial LLT
    21.0 100000004866 10043640 Thrombosis venous LLT
    23.1 100000004863 10051014 Post procedural bleeding LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) AT (Completed) NL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007943-29 Sponsor Protocol Number: EFC6521 Start Date*: 2008-07-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk ...
    Medical condition: The subjects who will participate to this clinical trial are cancer patients (i.e. patients with metastatic or locally advanced tumor of the lung, pancreas, stomach, colon/ rectum, bladder or ovary...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) FR (Completed) AT (Completed) LV (Completed) EE (Completed) SE (Completed) SK (Completed) NL (Completed) PT (Completed) LT (Completed) BE (Completed) DK (Completed) CZ (Completed) FI (Completed) SI (Completed) IT (Completed) BG (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000228-13 Sponsor Protocol Number: EFC10572 Start Date*: 2008-08-22
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical...
    Medical condition: The subjects who will partcipate to this clinical trial are acutely ill medical patients with restricted mobility.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) LV (Prematurely Ended) FR (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PT (Completed) EE (Completed) BE (Completed) LT (Prematurely Ended) IT (Prematurely Ended) PL (Completed) SI (Completed) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 10:27:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA